Compared to Estimates, Aquestive Therapeutics (AQST) Q2 Earnings: A Look at Key Metrics

Aquestive Therapeutics (AQST) reported Q2 2025 revenue of $10 million, representing a 50.2% year-over-year decline and missing the $11.07 million consensus estimate by 9.62%. While the company's EPS of -$0.14 beat the -$0.18 consensus estimate by 22.22%, the significant top-line contraction was largely driven by a 92.5% decrease in license and royalty revenue and a 50% drop in co-development fees, despite an 18% year-over-year increase in manufacture and supply revenue. AQST shares have underperformed the broader market, returning -2.7% over the past month compared to the S&P 500's +2.7%.

Analysis

Aquestive Therapeutics (AQST) reported a challenging second quarter for 2025, characterized by a significant top-line contraction that overshadows a minor bottom-line beat. Total revenue fell 50.2% year-over-year to $10 million, missing the Zacks Consensus Estimate by 9.62%. While the reported EPS of -$0.14 was a 22.22% positive surprise against the consensus of -$0.18, it represents a substantial deterioration from the -$0.03 EPS recorded in the prior-year quarter. A deeper look into the revenue composition reveals a critical divergence: the core Manufacture and supply segment showed strength, growing 18% year-over-year to $9.58 million and beating estimates. However, this growth was completely offset by a near-total collapse in License and royalty revenue, which plummeted 92.5% year-over-year, and a 50% decline in Co-development fees. This shift indicates a heavy, and perhaps risky, reliance on the manufacturing segment as higher-margin partnership revenues have evaporated. The stock's -2.7% return over the past month, in contrast to the S&P 500's +2.7% gain, reflects investor apprehension regarding this negative shift in the company's revenue mix and overall growth profile.

Key Decisions for Investors

• Investors should look beyond the headline EPS beat and focus on the severe 50.2% year-over-year revenue decline, which signals fundamental weakness in the company's licensing and partnership business model.
• The primary investment thesis for AQST must now be re-evaluated to center almost exclusively on its manufacturing and supply operations, which grew 18%, as other revenue streams have proven to be highly volatile and have sharply contracted.
• Given the stock's recent underperformance and the conflicting signals between segment performance and overall results, a cautious or neutral stance is warranted until management provides a clear strategy to either stabilize high-margin revenue streams or accelerate manufacturing growth to compensate for the shortfall.